http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 07:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+16/26776729.html si-local-file:///var/storage/secattach/20260716/26776729.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+16/26776729.html Thu, 16 Jul 2026 07:32:00 -0400 O.55071903 VRAX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+16/26776729.html si-local-file:///var/storage/secattach/20260716/26776729.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+16/26776729.html Thu, 16 Jul 2026 07:32:00 -0400 O.55071903 VRAX http://www.streetinsider.com/Corporate+News/Virax+Biolabs+reports+cash+of+%246.4M%2C+regains+Nasdaq+compliance/26776704.html <p>Virax Biolabs Group Limited (NASDAQ: VRAX) filed its fiscal year 2026 annual report on July 2, 2026, reporting cash of $6.4 million, total assets of $8.3 million, total liabilities of $1.0 million, and shareholders' equity attributable to ordinary shareholders of $7.3 million as of March 31, 2026.</p> <p>Research and development expenses rose to $3.7 million in fiscal 2026 from $2.0 million in fiscal 2025, while general and administrative expenses fell to $2.7 million from $4.0 million. Net loss narrowed to $5.0 million from $6.1 million in the prior year.</p> <p>Subsequent to fiscal year end, the company completed the exercise of preferred investment http://www.streetinsider.com/Corporate+News/Virax+Biolabs+reports+cash+of+%246.4M%2C+regains+Nasdaq+compliance/26776704.html Thu, 16 Jul 2026 07:30:25 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/Corporate+News/Virax+Biolabs+reports+cash+of+%246.4M%2C+regains+Nasdaq+compliance/26776704.html <p>Virax Biolabs Group Limited (NASDAQ: VRAX) filed its fiscal year 2026 annual report on July 2, 2026, reporting cash of $6.4 million, total assets of $8.3 million, total liabilities of $1.0 million, and shareholders' equity attributable to ordinary shareholders of $7.3 million as of March 31, 2026.</p> <p>Research and development expenses rose to $3.7 million in fiscal 2026 from $2.0 million in fiscal 2025, while general and administrative expenses fell to $2.7 million from $4.0 million. Net loss narrowed to $5.0 million from $6.1 million in the prior year.</p> <p>Subsequent to fiscal year end, the company completed the exercise of preferred investment http://www.streetinsider.com/Corporate+News/Virax+Biolabs+reports+cash+of+%246.4M%2C+regains+Nasdaq+compliance/26776704.html Thu, 16 Jul 2026 07:30:25 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/Corporate+News/Virax+Biolabs+reports+cash+of+%246.4M%2C+regains+Nasdaq+compliance/26776704.html <p>Virax Biolabs Group Limited (NASDAQ: VRAX) filed its fiscal year 2026 annual report on July 2, 2026, reporting cash of $6.4 million, total assets of $8.3 million, total liabilities of $1.0 million, and shareholders' equity attributable to ordinary shareholders of $7.3 million as of March 31, 2026.</p> <p>Research and development expenses rose to $3.7 million in fiscal 2026 from $2.0 million in fiscal 2025, while general and administrative expenses fell to $2.7 million from $4.0 million. Net loss narrowed to $5.0 million from $6.1 million in the prior year.</p> <p>Subsequent to fiscal year end, the company completed the exercise of preferred investment http://www.streetinsider.com/Corporate+News/Virax+Biolabs+reports+cash+of+%246.4M%2C+regains+Nasdaq+compliance/26776704.html Thu, 16 Jul 2026 07:30:25 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/Corporate+News/Virax+Biolabs+reports+cash+of+%246.4M%2C+regains+Nasdaq+compliance/26776704.html <p>Virax Biolabs Group Limited (NASDAQ: VRAX) filed its fiscal year 2026 annual report on July 2, 2026, reporting cash of $6.4 million, total assets of $8.3 million, total liabilities of $1.0 million, and shareholders' equity attributable to ordinary shareholders of $7.3 million as of March 31, 2026.</p> <p>Research and development expenses rose to $3.7 million in fiscal 2026 from $2.0 million in fiscal 2025, while general and administrative expenses fell to $2.7 million from $4.0 million. Net loss narrowed to $5.0 million from $6.1 million in the prior year.</p> <p>Subsequent to fiscal year end, the company completed the exercise of preferred investment http://www.streetinsider.com/Corporate+News/Virax+Biolabs+reports+cash+of+%246.4M%2C+regains+Nasdaq+compliance/26776704.html Thu, 16 Jul 2026 07:30:25 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/Press+Releases/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html <div class="xn-content"> <ul type="disc"><li>Fiscal 2026 Annual Report, filed <chron>July 2, 2026</chron>, reflects cash of <money>$6.4 million</money>, total assets of <money>$8.3 million</money> and shareholders' equity attributable to ordinary shareholders of <money>$7.3 million</money></li><li><span>Fosun Diagnostics</span> agreement, announced <chron>July 9, 2026</chron>, supports commercial execution for ImmuneSelect across six Southeast Asian markets</li><li>Preferred investment option exercise, completed <chron>July 10, 2026</chron>, generated approximately <money>$3.3 million</money> in gross proceeds, further strengthening the Company's liquidity position and balance sheet</li><li>Nasdaq confirmed on <chron>July 13, 2026</chron>, that the Company regained compliance with the minimum bid price requirement</li></ul><p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs http://www.streetinsider.com/Press+Releases/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html Thu, 16 Jul 2026 07:30:00 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/Press+Releases/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html <div class="xn-content"> <ul type="disc"><li>Fiscal 2026 Annual Report, filed <chron>July 2, 2026</chron>, reflects cash of <money>$6.4 million</money>, total assets of <money>$8.3 million</money> and shareholders' equity attributable to ordinary shareholders of <money>$7.3 million</money></li><li><span>Fosun Diagnostics</span> agreement, announced <chron>July 9, 2026</chron>, supports commercial execution for ImmuneSelect across six Southeast Asian markets</li><li>Preferred investment option exercise, completed <chron>July 10, 2026</chron>, generated approximately <money>$3.3 million</money> in gross proceeds, further strengthening the Company's liquidity position and balance sheet</li><li>Nasdaq confirmed on <chron>July 13, 2026</chron>, that the Company regained compliance with the minimum bid price requirement</li></ul><p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs http://www.streetinsider.com/Press+Releases/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html Thu, 16 Jul 2026 07:30:00 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/Press+Releases/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html <div class="xn-content"> <ul type="disc"><li>Fiscal 2026 Annual Report, filed <chron>July 2, 2026</chron>, reflects cash of <money>$6.4 million</money>, total assets of <money>$8.3 million</money> and shareholders' equity attributable to ordinary shareholders of <money>$7.3 million</money></li><li><span>Fosun Diagnostics</span> agreement, announced <chron>July 9, 2026</chron>, supports commercial execution for ImmuneSelect across six Southeast Asian markets</li><li>Preferred investment option exercise, completed <chron>July 10, 2026</chron>, generated approximately <money>$3.3 million</money> in gross proceeds, further strengthening the Company's liquidity position and balance sheet</li><li>Nasdaq confirmed on <chron>July 13, 2026</chron>, that the Company regained compliance with the minimum bid price requirement</li></ul><p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs http://www.streetinsider.com/Press+Releases/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html Thu, 16 Jul 2026 07:30:00 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/Press+Releases/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html <div class="xn-content"> <ul type="disc"><li>Fiscal 2026 Annual Report, filed <chron>July 2, 2026</chron>, reflects cash of <money>$6.4 million</money>, total assets of <money>$8.3 million</money> and shareholders' equity attributable to ordinary shareholders of <money>$7.3 million</money></li><li><span>Fosun Diagnostics</span> agreement, announced <chron>July 9, 2026</chron>, supports commercial execution for ImmuneSelect across six Southeast Asian markets</li><li>Preferred investment option exercise, completed <chron>July 10, 2026</chron>, generated approximately <money>$3.3 million</money> in gross proceeds, further strengthening the Company's liquidity position and balance sheet</li><li>Nasdaq confirmed on <chron>July 13, 2026</chron>, that the Company regained compliance with the minimum bid price requirement</li></ul><p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs http://www.streetinsider.com/Press+Releases/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html Thu, 16 Jul 2026 07:30:00 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/PRNewswire/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html <div class="xn-content"> <ul type="disc"><li>Fiscal 2026 Annual Report, filed <chron>July 2, 2026</chron>, reflects cash of <money>$6.4 million</money>, total assets of <money>$8.3 million</money> and shareholders' equity attributable to ordinary shareholders of <money>$7.3 million</money></li><li><span>Fosun Diagnostics</span> agreement, announced <chron>July 9, 2026</chron>, supports commercial execution for ImmuneSelect across six Southeast Asian markets</li><li>Preferred investment option exercise, completed <chron>July 10, 2026</chron>, generated approximately <money>$3.3 million</money> in gross proceeds, further strengthening the Company's liquidity position and balance sheet</li><li>Nasdaq confirmed on <chron>July 13, 2026</chron>, that the Company regained compliance with the minimum bid price requirement</li></ul><p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs http://www.streetinsider.com/PRNewswire/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html Thu, 16 Jul 2026 07:30:00 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/PRNewswire/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html <div class="xn-content"> <ul type="disc"><li>Fiscal 2026 Annual Report, filed <chron>July 2, 2026</chron>, reflects cash of <money>$6.4 million</money>, total assets of <money>$8.3 million</money> and shareholders' equity attributable to ordinary shareholders of <money>$7.3 million</money></li><li><span>Fosun Diagnostics</span> agreement, announced <chron>July 9, 2026</chron>, supports commercial execution for ImmuneSelect across six Southeast Asian markets</li><li>Preferred investment option exercise, completed <chron>July 10, 2026</chron>, generated approximately <money>$3.3 million</money> in gross proceeds, further strengthening the Company's liquidity position and balance sheet</li><li>Nasdaq confirmed on <chron>July 13, 2026</chron>, that the Company regained compliance with the minimum bid price requirement</li></ul><p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs http://www.streetinsider.com/PRNewswire/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html Thu, 16 Jul 2026 07:30:00 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/PRNewswire/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html <div class="xn-content"> <ul type="disc"><li>Fiscal 2026 Annual Report, filed <chron>July 2, 2026</chron>, reflects cash of <money>$6.4 million</money>, total assets of <money>$8.3 million</money> and shareholders' equity attributable to ordinary shareholders of <money>$7.3 million</money></li><li><span>Fosun Diagnostics</span> agreement, announced <chron>July 9, 2026</chron>, supports commercial execution for ImmuneSelect across six Southeast Asian markets</li><li>Preferred investment option exercise, completed <chron>July 10, 2026</chron>, generated approximately <money>$3.3 million</money> in gross proceeds, further strengthening the Company's liquidity position and balance sheet</li><li>Nasdaq confirmed on <chron>July 13, 2026</chron>, that the Company regained compliance with the minimum bid price requirement</li></ul><p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs http://www.streetinsider.com/PRNewswire/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html Thu, 16 Jul 2026 07:30:00 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/PRNewswire/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html <div class="xn-content"> <ul type="disc"><li>Fiscal 2026 Annual Report, filed <chron>July 2, 2026</chron>, reflects cash of <money>$6.4 million</money>, total assets of <money>$8.3 million</money> and shareholders' equity attributable to ordinary shareholders of <money>$7.3 million</money></li><li><span>Fosun Diagnostics</span> agreement, announced <chron>July 9, 2026</chron>, supports commercial execution for ImmuneSelect across six Southeast Asian markets</li><li>Preferred investment option exercise, completed <chron>July 10, 2026</chron>, generated approximately <money>$3.3 million</money> in gross proceeds, further strengthening the Company's liquidity position and balance sheet</li><li>Nasdaq confirmed on <chron>July 13, 2026</chron>, that the Company regained compliance with the minimum bid price requirement</li></ul><p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs http://www.streetinsider.com/PRNewswire/Virax+Biolabs%27+CEO+James+Foster+Provides+Shareholder+Update+Following+Fiscal+2026+Annual+Report+and+Fosun+Diagnostics+Commercial+Supply+Agreement/26776698.html Thu, 16 Jul 2026 07:30:00 -0400 A.09642568 O.20371933 O.55071903 VRAX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+10/26757406.html si-local-file:///var/storage/secattach/20260710/26757406.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+10/26757406.html Fri, 10 Jul 2026 16:07:00 -0400 O.55071903 VRAX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+10/26757406.html si-local-file:///var/storage/secattach/20260710/26757406.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+10/26757406.html Fri, 10 Jul 2026 16:07:00 -0400 O.55071903 VRAX http://www.streetinsider.com/Equity+Offerings/Virax+Biolabs+to+raise+%243.3M+via+preferred+option+exercise/26752536.html <p>Virax Biolabs Group Limited (Nasdaq: VRAX) has entered into a definitive agreement for the exercise of certain outstanding preferred investment options, expecting to generate approximately $3.3 million in gross proceeds before placement agent fees and offering expenses.</p><p>The agreement covers the exercise of options to purchase up to 548,000 ordinary shares at a reduced price of $6.00 per share, down from an original exercise price of $10.00. The options were originally issued in October 2023, amended in December 2025, and in December 2025.</p><p>In exchange for the immediate cash exercise, the company will issue two new series of unregistered warrants. The Series http://www.streetinsider.com/Equity+Offerings/Virax+Biolabs+to+raise+%243.3M+via+preferred+option+exercise/26752536.html Thu, 09 Jul 2026 13:36:11 -0400 VRAX http://www.streetinsider.com/Corporate+News/Virax+Biolabs+to+raise+%243.3M+via+preferred+option+exercise/26752536.html <p>Virax Biolabs Group Limited (Nasdaq: VRAX) has entered into a definitive agreement for the exercise of certain outstanding preferred investment options, expecting to generate approximately $3.3 million in gross proceeds before placement agent fees and offering expenses.</p><p>The agreement covers the exercise of options to purchase up to 548,000 ordinary shares at a reduced price of $6.00 per share, down from an original exercise price of $10.00. The options were originally issued in October 2023, amended in December 2025, and in December 2025.</p><p>In exchange for the immediate cash exercise, the company will issue two new series of unregistered warrants. The Series http://www.streetinsider.com/Corporate+News/Virax+Biolabs+to+raise+%243.3M+via+preferred+option+exercise/26752536.html Thu, 09 Jul 2026 13:36:11 -0400 VRAX http://www.streetinsider.com/Press+Releases/Virax+Biolabs+Group+Limited+Announces+Exercise+of+Preferred+Investment+Options+for+%243.3+Million+Gross+Proceeds/26752533.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs Group Limited</span> ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value <money>$0.025</money> (the "Ordinary Shares") originally issued in <chron>October 2023</chron> (as amended in <chron>December 2025</chron>) and in <chron>December 2025</chron> having an original exercise price of <money>$10.00</money> per share, at a reduced exercise price of <money>$6.00</money> per share.  The resale of the http://www.streetinsider.com/Press+Releases/Virax+Biolabs+Group+Limited+Announces+Exercise+of+Preferred+Investment+Options+for+%243.3+Million+Gross+Proceeds/26752533.html Thu, 09 Jul 2026 13:35:00 -0400 O.55071903 VRAX http://www.streetinsider.com/Press+Releases/Virax+Biolabs+Group+Limited+Announces+Exercise+of+Preferred+Investment+Options+for+%243.3+Million+Gross+Proceeds/26752533.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs Group Limited</span> ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value <money>$0.025</money> (the "Ordinary Shares") originally issued in <chron>October 2023</chron> (as amended in <chron>December 2025</chron>) and in <chron>December 2025</chron> having an original exercise price of <money>$10.00</money> per share, at a reduced exercise price of <money>$6.00</money> per share.  The resale of the http://www.streetinsider.com/Press+Releases/Virax+Biolabs+Group+Limited+Announces+Exercise+of+Preferred+Investment+Options+for+%243.3+Million+Gross+Proceeds/26752533.html Thu, 09 Jul 2026 13:35:00 -0400 O.55071903 VRAX http://www.streetinsider.com/PRNewswire/Virax+Biolabs+Group+Limited+Announces+Exercise+of+Preferred+Investment+Options+for+%243.3+Million+Gross+Proceeds/26752533.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs Group Limited</span> ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value <money>$0.025</money> (the "Ordinary Shares") originally issued in <chron>October 2023</chron> (as amended in <chron>December 2025</chron>) and in <chron>December 2025</chron> having an original exercise price of <money>$10.00</money> per share, at a reduced exercise price of <money>$6.00</money> per share.  The resale of the http://www.streetinsider.com/PRNewswire/Virax+Biolabs+Group+Limited+Announces+Exercise+of+Preferred+Investment+Options+for+%243.3+Million+Gross+Proceeds/26752533.html Thu, 09 Jul 2026 13:35:00 -0400 O.55071903 VRAX http://www.streetinsider.com/PRNewswire/Virax+Biolabs+Group+Limited+Announces+Exercise+of+Preferred+Investment+Options+for+%243.3+Million+Gross+Proceeds/26752533.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VRAX" idsrc="xmltag.org" >Virax Biolabs Group Limited</span> ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value <money>$0.025</money> (the "Ordinary Shares") originally issued in <chron>October 2023</chron> (as amended in <chron>December 2025</chron>) and in <chron>December 2025</chron> having an original exercise price of <money>$10.00</money> per share, at a reduced exercise price of <money>$6.00</money> per share.  The resale of the http://www.streetinsider.com/PRNewswire/Virax+Biolabs+Group+Limited+Announces+Exercise+of+Preferred+Investment+Options+for+%243.3+Million+Gross+Proceeds/26752533.html Thu, 09 Jul 2026 13:35:00 -0400 O.55071903 VRAX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+09/26750148.html si-local-file:///var/storage/secattach/20260709/26750148.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+09/26750148.html Thu, 09 Jul 2026 07:34:00 -0400 O.55071903 VRAX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+09/26750148.html si-local-file:///var/storage/secattach/20260709/26750148.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Virax+Biolabs+Group+Ltd+++For%3A+Jul+09/26750148.html Thu, 09 Jul 2026 07:34:00 -0400 O.55071903 VRAX http://www.streetinsider.com/Corporate+News/Virax+Biolabs+signs+supply+deal+with+Fosun+Diagnostics+for+SE+Asia/26750116.html <p>Virax Biolabs Group Limited (NASDAQ: VRAX) announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia.</p> <p>Under the agreement, Virax will supply its ImmuneSelect research-use-only immune profiling product line, including ELISpot assay plates used to measure cellular immune responses, to Fosun Diagnostics under purchase orders. Exclusivity is subject to agreed minimum purchase and performance requirements. Pricing includes volume-based tiers. The initial focus is tuberculosis-related research applications in Thailand, with planned rollout across the other five markets.</p> <p>ImmuneSelect http://www.streetinsider.com/Corporate+News/Virax+Biolabs+signs+supply+deal+with+Fosun+Diagnostics+for+SE+Asia/26750116.html Thu, 09 Jul 2026 07:30:17 -0400 O.55071903 VRAX